Zhejiang Huahai Pharmaceutical Co Ltd
Research Zhejiang Huahai Pharmaceutical Co Ltd (600521.SS) on Bullrun: market cap CNY 25.84B, P/E 27.3, dividend yield 0.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker600521.SS
- ExchangeSS
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCNY
- Market capCNY 25.84B
- P/E27.3
- Dividend yield0.6%
- Financial periodQ2 2026
- RevenueCNY 2.58B
- Net incomeCNY 366.73M
- Free cash flowCNY 423.34M
- Gross margin59.1%
Valuation Snapshot
latest market cap is CNY 25.84B; P/E is 27.3; dividend yield is 0.6%.
Peer valuation comparison
Latest P/E is 27.35x versus a Healthcare sector median of 21.8x (25.5% above).
Latest dividend yield is 0.58% versus a Healthcare sector median of 2.4% (75.8% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | CNY 25.84B | 27.3 | 0.6% | 0.1 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.1 CNY, yield 0.6%.
About Zhejiang Huahai Pharmaceutical Co Ltd
Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production, and sales of generic drugs, biologics, drugs, and specialty active pharmaceutical ingredients in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as polyethylene bottles and polypropylene caps for pharmaceuticals.
ETFs that hold Zhejiang Huahai Pharmaceutical Co Ltd
US-listed ETFs
Zhejiang Huahai Pharmaceutical Co Ltd is held by 21 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | <0.01% | 0.04% |
| Schwab Emerging Markets Equity ETF (SCHE) | <0.01% | 0.06% |
| State Street SPDR Portfolio Emerging Markets ETF (SPEM) | <0.01% | 0.07% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Zhejiang Huahai Pharmaceutical Co Ltd's market cap?
Zhejiang Huahai Pharmaceutical Co Ltd's market capitalization is CNY 25.84B.
What is Zhejiang Huahai Pharmaceutical Co Ltd's P/E ratio?
Zhejiang Huahai Pharmaceutical Co Ltd's price-to-earnings (P/E) ratio is 27.3.
Does Zhejiang Huahai Pharmaceutical Co Ltd pay a dividend?
Zhejiang Huahai Pharmaceutical Co Ltd has a dividend yield of 0.6%.
What does Zhejiang Huahai Pharmaceutical Co Ltd do?
Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production, and sales of generic drugs, biologics, drugs, and specialty active pharmaceutical ingredients in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as polyethylene bottles and polypropylene caps for pharmaceuticals. In addition, the company offers contract manufacturing and other services, as well as import and export trade services.